You are here: Industry Insights > Seattle Genetics

News List

US expands scope of Seattle Genetics’ Adcetris pharmatimes
July 23, 2018
US regulators have approved Seattle Genetics’ Adcetris in combination with chemotherapy for adult patients with previously untreated Stage III or IV classical Hodgkin lymphoma.
Seattle Genetics Gains Another FDA Approval biospace
March 22, 2018
Seattle Genetics, Inc. announced that FDA had approved its Adcetris in combination with chemotherapy in adults with previously untreated Stage III or IV classical Hodgkin lymphoma.
Seattle Genetics exercises option to co-develop tisotumab vedotin for solid tumours pharmaceutical-technology
August 31, 2017
Danish biotechnology company Genmab and US-based Seattle Genetics are set to co-develop tisotumab vedotin for the treatment of patients with solid tumours.
Deals this week: Innoviva, Seattle Genetics, PlasmaGen BioSciences pharmaceutical-technology
August 07, 2017
US-based small molecule medicines provider Innoviva (formerly Advanced Medicine) has announced a private placement of convertible senior notes due 2025 to raise $175m.
Deals this week: Innoviva, Seattle Genetics, PlasmaGen BioSciences pharmaceutical-technology
August 04, 2017
US-based small molecule medicines provider Innoviva (formerly Advanced Medicine) has announced a private placement of convertible senior notes due 2025 to raise $175m.
Seattle Genetics halts trials of latest ADC after safety warning pharmaphorum
June 22, 2017
Seattle Genetics has halted all trials of its vadastuximab talirine after a review uncovered a high death rate in acute myeloid leukaemia patients treated with the drug.

Previous page 1 2 Next page